



**Food and Drug Administration Advisory Committee Member
Acknowledgment of Financial Interests**

Name of Advisory Committee Member: **Jean-Pierre Raufman, M.D.**

Committee: Gastrointestinal Drugs Advisory Committee (GIDAC)

Meeting Date: March 8, 2018

I acknowledge that contingent upon public disclosure of the following financial interests related to the agenda item: Supplemental new drug application (sNDA) 203214, supplement 18, XELJANZ (tofacitinib) 5 mg and 10 mg tablets, submitted by Pfizer Inc., proposed for the treatment of adult patients with moderately to severely active ulcerative colitis who have demonstrated an inadequate response, loss of response or intolerance to corticosteroids, azathioprine, 6-mercaptopurine or tumor necrosis factor (TNF) inhibitor therapy, I may be considered for participation in the advisory committee meeting described above.

| <u>Type of Interest</u> | <u>Nature</u> | <u>Magnitude</u> |
|-------------------------------------|--------------------------|-------------------------|
| I. Personal/Immediate Family | | |
| None | | |
| II. Other Imputed Interests | | |
| Employer's research contracts | Celgene (competing firm) | \$0 - \$50,000 per year |
| | AbbVie (competing firm) | \$0 - \$50,000 per year |
| | AbbVie (competing firm) | \$0 - \$50,000 per year |
| | AbbVie (competing firm) | \$0 - \$50,000 per year |
| | Takeda (competing firm) | \$0 - \$50,000 per year |

I hereby request that FDA make this information publicly available on my behalf if the agency grants a waiver allowing me to participate in the meeting described above. I understand that without public disclosure of these interests, I will not participate in the advisory committee meeting described above.

_____/S/_____
Signature

Date 2/9/2018